600867 Tonghua Dongbao Pharmaceutical

We Ran A Stock Scan For Earnings Growth And Tonghua Dongbao Pharmaceutical (SHSE:600867) Passed With Ease

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the

03-15 08:47

Are Strong Financial Prospects The Force That Is Driving The Momentum In Tonghua Dongbao Pharmaceutical Co., Ltd.'s SHSE:600867) Stock?

Tonghua Dongbao Pharmaceutical (SHSE:600867) has had a great run on the share market with its stock up by a significant 25% over the last three months. Since the market usually pay for a company's l

02-22 08:16

Guojin Securities: The GLP-1 market continues to expand, and there are huge opportunities for domestic substitution

The Zhitong Finance App learned that Guojin Securities released a research report saying that the GLP-1 market is still growing rapidly. Currently, 9% of diabetics in the world use GLP-1, but it contributes 31% of the sales revenue of hypoglycemic drugs. GLP-1 is expanding into frontline treatment and is taking down or exploring many major indications such as obesity, NASH, CKD, and AD. In the foreseeable future, the global and Chinese GLP-1 markets will maintain rapid growth in the next few years, and there are huge opportunities for domestic substitution in the domestic market. In terms of specific configuration, the bank suggests focusing on global and domestic development progress in the GLP-1 field.

02-14 10:32

Changes in A-shares | Tonghua Dongbao rose more than 8% and sales of existing products are expected to grow steadily

Gelonghui, Feb. 9 | Tonghua Dongbao (600867.SH) rose sharply by more than 8% in the afternoon. It is now reported that 11.26 yuan hit a new high price in 15 months, with a total market value of 22.5 billion yuan. The company recently announced its results, with a net profit of 1,589 million yuan in 2022, an increase of 21.46% over the previous year. CICC believes that sales of the company's existing products are expected to grow steadily, and that the launch of new products will bring room for growth. The company expects that if approved, it will greatly speed up the registration process for the company's human insulin products in many overseas countries.

02-09 13:27

Tonghua Dongbao Pharmaceutical Enrolls First Subject for Phase II Trial of Gout Drug; Shares Rose 4%

01:08 AM EST, 02/08/2023 (MT Newswires) -- Tonghua Dongbao Pharmaceutical (SHA:600867) unit, Dongbao Zixing (Hangzhou) Biomedical, enrolled its first subject for the Phase II clinical trial of its THD

02-08 14:11

Tonghua Dongbao: Phase II clinical trial of URAT1 inhibitor (THDBH130 tablets) completed the first patient enrollment

02-07 16:29

Tonghua Dongbao Pharma’s Net Profit Jumps 21% Despite Revenue Drop

12:41 AM EST, 02/07/2023 (MT Newswires) -- Tonghua Dongbao Pharmaceutical (SHA:600867) reported a 21.5% year-over-year jump in net profit in 2022 even as the Chinese drugmaker posted lower revenue. Ne

02-07 13:42

Tonghua Dongbao (600867): The forecast for deducting non-net profit is in line with expectations, further advancing R&D and internationalization strategies

　　Forecasting a 23.45% year-on-year decrease in non-net profit, the company released its 2022 earnings forecast: 2022 revenue was 2,775 billion yuan, a year-on-year decrease of 15.09%. Guimu's net profit was 1,589 million yuan, an increase of 21.46% over the previous year (mainly due to the company's investment income from the sale of some of Tebao Biotech's shares). Deducting non-net profit of 846 million yuan, a year-on-year decrease of 23.45% (mainly due to the impact of the pandemic and collection), is in line with our expectations. Key points of concern are that revenue for the fourth quarter was affected by the pandemic. Company 4Q22 operating income 6.

02-07 09:26 · Researches

Tonghua Dongbao (600867.SH) performance report: 2022 deduction of non-net profit of 846 million yuan, a year-on-year decrease of 23.45%

Gelonghui, Feb. 6 丨 Tonghua Dongbao (600867.SH) released its 2022 annual performance report, achieving operating income of 2,775 million yuan, a decrease of 15.09% over the previous year; net profit attributable to shareholders of listed companies of 1,589 million yuan, an increase of 21.46% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 846 million yuan, a decrease of 23.45% over the previous year; and basic earnings per share of 0.80 yuan. The main factors affecting operating income: Since May 2022, national insulin collection has been implemented in various provinces and cities, and the prices of all series of the company's insulin products are higher than those collected

02-06 15:40

Tonghua Dongbao Performance Report: Net profit increased 21.46% year-on-year in 2022

02-06 15:34